Join Growin Stock Community!

Nucana plcNCNA.US Overview

US StockHealthcare
(No presentation for NCNA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

NCNA AI Insights

NCNA Overall Performance

NCNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NCNA Recent Performance

-0.36%

Nucana plc

0.05%

Avg of Sector

-0.31%

S&P500

NCNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

NCNA Key Information

NCNA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

NCNA Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Price of NCNA

NCNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NCNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.53
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.25
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.53
PE Ratio (TTM)
0.01
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
0.25
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NCNA's latest earnings report released?

    The most recent financial report for Nucana plc (NCNA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NCNA's short-term business performance and financial health. For the latest updates on NCNA's earnings releases, visit this page regularly.

  • How much debt does NCNA have?

    As of the end of the reporting period, Nucana plc (NCNA) had total debt of 136K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NCNA have?

    At the end of the period, Nucana plc (NCNA) held Total Cash and Cash Equivalents of 25.25M, accounting for 0.78 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NCNA's EPS continuing to grow?

    According to the past four quarterly reports, Nucana plc (NCNA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of NCNA?

    Nucana plc (NCNA)'s Free Cash Flow (FCF) for the period is -1.71M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 62.83% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.